Incyte | Skyworks Solutions | Splunk | ANSYS | United Airlines Holdings | Alexion has employed a strategy of developing drugs to combat rare diseases. Xilinx | PharmaVitae explores the rationale for accelerated dealmaking in 2018, earmarking companies touted for M&A activity, and details 27 targets that potential acquirers should prioritize based on strategic themes, KOL interviews, and physician surveys. CDW Corporation | Eculizumab wird in zahlreichen weiteren Indikationen (Antibody Mediated Rejection (AMR) - Living and Deceased Donor, Delayed Graft Function (DGF), Relapsing Neuromyelitis Optica (NMO), Severe and Refractory Myasthenia Gravis (MG), Shiga-toxin E. coli-Related (STEC) HUS) untersucht. Alexion’s growth has been predominantly dependent on Soliris, as the drug represented 79% of 2019 total net product sales. Alexion Pharmaceuticals, Inc. is committed to researching rare diseases and investigating potential new treatments that have the possibility of transforming patients' lives. Costco | High-impact upcoming events comprise and topline Phase III trial results for Ultomiris and WTX101. Upcoming Catalysts Cadence Design Systems | In July 2020, Alexion completed acquisition of Portola for $1.44 billion. See if … Fastenal | Alexion Pharmaceuticals | Ross Stores | Alexion Page 1 of 32 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrSTRENSIQ® (asfotase alfa) Solution for Injection 40 mg/mL & 100 mg/mL Enzyme Replacement Therapy ATC code: A16AB13 Alexion Pharma GmbH Giesshübelstrasse 30 CH - 8045 Zürich, Switzerland Control No: 204145 With the share price depressed, activist investor Elliott Advisors had urged Alexion to consider a sale. Microchip Technology | Western Digital | This document is a licensed product and is not to be reproduced or redistributed. The acquisition added Andexxa, a factor Xa reversal agent approved in the US and Europe. Ultomiris forecast adjusted higher due to continued faster switching from Soliris. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced today a collaboration and license agreement that enables Alexion to use Halozyme’s ENHANZE ® drug-delivery technology in the development of subcutaneous formulations for their portfolio of products. Alexion's goal is always to manage a robust supply chain that delivers medicines that are secure, sterile and meet our rigorous quality standards. Alexion is collaborating with Dicerna to jointly discover and develop subcutaneously … Therapy Area Outlook Ultomiris forecast adjusted higher due to faster switching from Soliris, tempered somewhat by an impact to new patient starts from COVID-19. Cisco | See full prescribing information for SOLIRIS. Tesla, Inc. | Medications listed here may also be marketed under different names in different countries. Ulta Beauty | Recent Insights, Clinical Trial Overview In December 2020, AstraZeneca and Alexion Pharmaceuticals entered into a definitive agreement for AstraZeneca to acquire Alexion. It employs around 2,400 people worldwide. CVD is the leading cause of death globally, responsible for over 17 million deaths annually. Cognizant Technology Solutions | Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). More than 2/3 of PNH patients in major markets have switched from Soliris to Ultomiris. PharmaVitae explores Alexion’s prescription pharmaceutical performance and outlook over 2019–29. Regeneron Pharmaceuticals | PepsiCo | Fiserv | Clinical Trial Snapshot 2.500 Mitarbeiter. Clinical Trials by Status and Phase [3] [4] The company is also involved in immune system research related to autoimmune diseases. Any threat to that drug, called Soliris, could acutely affect the company's health. Phase 3 development is being initiated for danicopan as an add-on therapy for PNH patients with extravascular hemolysis (EVH). Additionally, big pharmaceutical companies have tended to ignore these markets, creating a niche with minimal competition for Alexion. Biogen | PharmaVitae explores Alexion’s prescription pharmaceutical performance and outlook over 2019–29. You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. Align Technology | [1], Activision Blizzard | Advanced Micro Devices | Insurance companies have generally been willing to pay high prices for such drugs; since few of their customers need the drugs, a high price does not significantly impact t… Cerner Corporation | [5][3], 2020 erwirtschaftete das Unternehmen einen Umsatz von 6,1 Mrd. Key Metrics Lifecycle Analysis, Company Profile Alexion indications and usages, prices, online pharmacy health products information We have taken proactive measures to mitigate the risk of potential interruptions in supply, and we are … Das Unternehmen ist auf Orphan-Arzneimittel zur Behandlung von seltenen und sehr seltenen Krankheiten spezialisiert. Earnings Overview NetEase | Andexxa forecast added due to acquisition of Portola Pharmaceuticals. Clinical Trials by Drug, © Informa UK Ltd. The push intensified following acquisitions of two biotechs, both of which were met with considerable skepticism. Starbucks | Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today reported that Soliris(R) (eculizumab), its first-in-class complement inhibitor, has been designated as an orphan drug by the Ministry of Health, Labour and Welfare of Japan. Alexion wurde 1992 unter anderem von Leonard Bell gegründet, einem Professor für Innere Medizin und Pathologie an der Yale University. Alexion will continue development of Achillion’s oral Factor D inhibitor portfolio, which includes two clinical-stage medicines-in-development – danicopan (ACH-4471) and ACH-5228 – as well as multiple compounds in preclinical development. Mondelēz International | Easy 1-Click Apply (ALEXION PHARMACEUTICALS) Associate Scientist IV, Injectable Drug Product Development job in New Haven, CT. View job description, responsibilities and qualifications. Recent Events & Analyst Opinions Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. The agreement provides Alexion with the opportunity for exclusive development … Applied Materials | T-Mobile US | CSX Corporation | Prescription Pharmaceuticals Sales Outlook Registered in England and Wales. Most patients with severe and life-threatening rare diseases live with no effective treatment options and no hope. Lam Research | Amazon.com | Company Overview Alexion compares favorably to most peers over the near-term (2019-2024) and unfavorably in long-term (2024-2029) revenue growth rates. Company Comparison, Recent Earnings Review The Kraft Heinz Company | Texas Instruments | Soliris revenues will be driven by uptake in neurology due to recent approvals in myasthenia gravis (MG) and neuromyelitis optica spectrum disorder (NMOSD). Degos disease-Wikipedia. Copart | Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? The position leads and directs the formulation and process development, product integration, and manufacturing of patient-centered injectable drug products for Alexion's diverse portfolio spanning synthetic, peptide, nucleic acid-and protein-based modalities across various liquid, lyophilized, vial, prefilled and cartridge-based presentations. Netflix | Number 8860726, We use cookies to improve your website experience. Illumina | Zoom Video Communications, atypischen Hämolytisch-Urämischen Syndroms, refraktären AChR-AK-positiven generalisierten Myasthenia Gravis, Molybdän-Cofaktor-Defizienz (MoCD) Type A, Alexion Reports Fourth Quarter and Full Year 2020 Results, Alexion Pharmaceuticals Inc. moving headquarters to Boston, https://de.wikipedia.org/w/index.php?title=Alexion_Pharmaceuticals&oldid=208640957, „Creative Commons Attribution/Share Alike“. Alexion’s growth has been predominantly dependent on Soliris, as the drug represented 79% of 2019 total net product sales. Sales in Europe and Japan are expected to grow with recent European and Japanese regulatory approvals of Ultomiris for atypical hemolytic uremic syndrome (aHUS). Intel | Adobe Inc. | Soliris forecast adjusted lower due to faster switching to Ultomiris as well as an impact to new patient starts from COVID-19. Alexion Pharmaceuticals ist ein biopharmazeutisches Unternehmen mit Sitz in Boston. [5] Februar 2021 um 21:28 Uhr bearbeitet. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. To learn about our use of cookies and how you can manage your cookie settings, please see our, Pharma Intelligence Report Store Newsletter. Easy 1-Click Apply (ALEXION PHARMACEUTICALS) Research Scientist I, Injectable Drug Product Development job in New Haven, CT. View job description, responsibilities and qualifications. Electronic Arts | Alexion is a leading global biopharmaceutical company, with total revenues of almost $5 billion in 2019. Take-Two Interactive | Regional Sales Outlook Intuitive Surgical | o Drug Substance: o Drug Product: Alexion Fill size and dosage form: 300mg/30mL vial Dating period: o Drug Product: 24 months: 2-8 °C o Drug Substance: o Results of on-going stability should be submitted throughout the dating period, as they become available, including the results of stability studies from the first three production lots. Marriott International | eBay | Paychex | Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Im Jahr 2018 verlagerte das Unternehmen seinen Hauptsitz von New Haven in Connecticut nach Boston. The American College of Cardiology (ACC) 66th Scientific Session was held in Washington, DC from 17–19 March 2017. Verisk Analytics | Pharma Insights Analysis, Company Forecast Paccar | Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Key Drug & Company Information Since the targeted user base is small for such drugs, clinical drugs tend to be quicker and cheaper than those for mass market drugs. Clinical Trials by Country IDEXX Laboratories | Alexion may see slow revenue growth due to patient switching from Soliris to Ultomiris, which has a lower annual average cost but a longer period of exclusivity. Seagen | US-Dollar) beruhen. Charter Communications | Booking Holdings | In January 2020, Alexion acquired Achillion for $930 million. The company is expected to generate more than 35% of revenue from launch products in 2025, which is higher than peer average. MercadoLibre | Diseases of the central nervous system (CNS) offer considerable opportunity to drug developers and marketers. Soliris forecast adjusted higher due to strength in neurology indications. Analog Devices | JD.com | PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. Qualcomm | Alexion wird an der NASDAQ gehandelt und ist im NASDAQ-100 gelistet. Alexion Pharmaceuticals ist ein biopharmazeutisches Unternehmen mit Sitz in Boston. Alphabet | Alexion – Speziell für Menschen mit seltenen Erkrankungen Alexion Pharmaceuticals ist ein weltweit tätiges, biopharmazeutisches Unternehmen, das sich auf die Entwicklung von lebensverändernden Therapien für Patienten mit seltenen Krankheiten spezialisiert hat, für die bislang keine wirksamen Behandlungsmöglichkeiten verfügbar sind. Cintas | Microsoft | By 2016, Bancel told an audience of JPMorgan Chase investors that the work with Alexion would shortly enter human trials. The global market for vascular stents is being driven by the increasing prevalence of cardiovascular disease (CVD). Dezember 2020 wurde bekannt, dass AstraZeneca für 39 Milliarden Dollar Alexion übernehmen wird. CoStar Group | Broadcom Inc. | O’Reilly Auto Parts | Nvidia | Liberty Global | Alexion is a leading global biopharmaceutical company, with total revenues of almost $5 billion in 2019. Fox Corporation | Monster Beverage | Check Point | The acquisition added two oral factor D inhibitors, danicopan (ACCH4771) and ACH-5228, to treat rare diseases associated with the complement alternative pathway to Alexion’s clinical-stage pipeline. Position Summary. Pending collection of 12-month safety and drug-device combination data, Alexion plans to file for approval in the U.S. and EU for the ULTOMIRIS SC formulation and device combination in PNH and aHUS in the third quarter of 2021. Launch Profile Outlook Beacon manufactures more than 200 generic drugs and 65 oncology products. Soliris forecast adjusted lower due to faster switching to Ultomiris.